Triptolide holds promise for reversing drug resistance across cancers, including NSCLC, prostate, and liver cancers, by enhancing chemosensitivity through mechanisms such as down-regulation of P-gp at both mRNA and protein levels, inhibition of the HNF1A/SHH and Keap1/NRF2 pathways [986]. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.